As 2024 draws to a close, the question on everyone’s mind is — What’s next for medical affairs in 2025? With the healthcare landscape changing at an unprecedented pace, staying ahead means understanding the trends that will define the year ahead. From digital transformation to patient-centric strategies, these shifts are already reshaping the way medical affairs teams operate. Here’s what you need to know to stay prepared and relevant.
A new report from The King’s Fund, NHS and Life Sciences Industry Partnerships: Collaborating to Improve Care, shows how working together can help the NHS improve care. The NHS is under pressure, and joining forces with the life sciences sector could bring in new ideas, tools, and support.
The pharmaceutical landscape is moving fast, and the importance of omnichannel engagement is becoming clear. Especially when it comes to reaching healthcare professionals (HCPs), and more specifically, Key Opinion Leaders (KOLs). These experts are at the forefront of medical advancements and reaching them in the right way can make all the difference. With the right omnichannel approach, you can build deeper, more meaningful relationships that cater to their unique preferences—helping them make decisions more efficiently in this ever-changing, complex field.
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has announced a 12-month extension to its substantial reform of the Medical Device Regulations, which will now come into force by July 2024.
Last year, our colleague Dr Zubair Hussain, Chairman of LE4D Global Regulatory and a PharmaMedic partner, provided an insightful strategic update on critical regulatory trends at PharmaMedic's inaugural virtual breakfast briefing. In this new article, we sat down with Dr Hussain once again to learn his latest insights on the three key issues he tips for the top of the regulatory agenda over the coming months. Read on to find out more.
Many thanks to LBIC and Lucy Garnsworthy for featuring PharmaMedic’s insights on recent UK government initiatives to support pharma and medicaldevices regulatory innovation in its winter newsletter. The article features on page 6 of the newsletter.
We enjoyed a very engaging session for our latest virtual breakfast briefing examining the UK's role in the international life sciences community from innovation and regulatory perspectives. If you missed the event, or would like to recap the key takeaways, read our summary, and catch up with the recording here.
With the government, the MHRA has launched a new consultation to shape a new era of medical device regulation in the UK. The objective is to create a framework that improves patient and public safety, increases transparency in regulatory decision-making, and aligns with global best practices. In this article, we summarise the issues and the scope of the potential changes.
